Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Drops By 40.6%

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 49,300 shares, a drop of 40.6% from the February 28th total of 83,000 shares. Based on an average daily volume of 2,640,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 6.6% of the shares of the company are short sold.

Windtree Therapeutics Stock Performance

Windtree Therapeutics stock opened at $1.56 on Monday. The firm has a market capitalization of $1.17 million, a PE ratio of -0.09 and a beta of 0.68. The stock’s 50 day moving average price is $4.74 and its 200 day moving average price is $31.46. Windtree Therapeutics has a one year low of $1.45 and a one year high of $737.44.

Institutional Trading of Windtree Therapeutics

An institutional investor recently bought a new position in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new stake in Windtree Therapeutics, Inc. (NASDAQ:WINT) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned 1.08% of Windtree Therapeutics at the end of the most recent reporting period. Institutional investors own 29.33% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating and issued a $350.00 price target on shares of Windtree Therapeutics in a report on Wednesday, December 4th.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.